Fresenius Kabi AG Announces Launch of Oxaliplatin Injection, USP  
8/9/2012 10:34:37 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE) -- Fresenius Kabi today announced that is has launched Oxaliplatin Injection, USP. Oxaliplatin Injection, USP, is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, and indicated for adjuvant therapy of stage III colon cancer in patients who have undergone complete resection of the primary tumor as well as for the treatment of advanced colorectal cancer.